Neuronetics, Inc. (STIM) |
| 2.13 -0.01 (-0.47%) 10-09 16:00 |
| Open: | 2.14 |
| High: | 2.2 |
| Low: | 2.11 |
| Volume: | 551,931 |
| Market Cap: | 148(M) |
| PE Ratio: | -4.84 |
| Exchange: | NASDAQ Global Market |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 3.25 |
| Resistance 1: | 2.81 |
| Pivot price: | 2.45 |
| Support 1: | 2.11 |
| Support 2: | 1.76 |
| 52w High: | 3.44 |
| 52w Low: | 0.8 |
Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents. These currents are specifically engineered to activate brain areas that are key to mood regulation. Neuronetics distributes its offerings directly to psychiatrists through its dedicated sales and client support personnel. Established in 2001, the company's corporate headquarters are situated in Malvern, Pennsylvania.
| EPS | -0.430 |
| Book Value | 0.230 |
| PEG Ratio | 0.00 |
| Gross Profit | 1.005 |
| Profit Margin (%) | -19.62 |
| Operating Margin (%) | -3.61 |
| Return on Assets (ttm) | -10.6 |
| Return on Equity (ttm) | -116.1 |
Thu, 08 Oct 2026
Neuronetics announced EHR integration and Neuronetics stock fell 3.06 percent - AD HOC NEWS
Wed, 19 Aug 2026
Neuronetics (NASDAQ: STIM) ex-officer lines up $464K stock sale - Stock Titan
Fri, 14 Aug 2026
US$6.00 - That's What Analysts Think Neuronetics, Inc. (NASDAQ:STIM) Is Worth After These Results - Simply Wall Street
Fri, 14 Aug 2026
Point72 discloses 5% Neuronetics (STIM) stake in new SEC ownership filing - Stock Titan
Tue, 11 Aug 2026
Neuronetics Q2 Earnings Call Highlights - TradingView
Tue, 11 Aug 2026
Neuronetics STIM Draws Buy Rating As Vertical Psychiatry Platform Scales Up - StocksToTrade
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |